Europe PMCopen access
Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer's disease
Cognitive function, Alzheimer’s disease, Glucagon-like Peptide-1 Receptor Agonist, Phase 3 Trial, Semaglutide, Small Vessel Pathology
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 642368
Conceptio Open Knowledge Archive — every document is proof-bundled with source, license, and retrieval metadata.